Friday 6 November 2026 Export BIO’s income statement to Excel — free account

Bio-Rad Laboratories, Inc.

BIO Healthcare Medical Devices

Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.

Revenue: +0.52%
EPS: +234.8%
Free cash flow: +8.07%
Total debt: +0.11%

Quarter to September 2026, against a year earlier

Operating cash flow growth 3 yrs

382.51 13.51 +3.66%

Follow BIO

Alert me

Market cap: $9.9B
P/E: 10.0×
Fwd P/E: 44.7×
Dividend yield: —
F-score: 5/9
Altman Z: 3.20
Beneish M: −2.29
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Bio-Rad Laboratories, Inc. 10-Q filed Aug 4, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed Aug 4, 2026 · accepted 4:20 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part II, Item 1A, Risk Factors, against the 10-Q filed Apr 30, 2026: 9 modified; 2 with only figures updated